Savills Hong Kong Hosts Grand Reception to Celebrate 40th Anniversary 
Micro-Dramas After 1 September 2026 – How China (Mainland) Rewrote the Rules 
Hong Kong, Singapore, Tokyo: A Data Centre Comparison for Asian Site Selection 
The Exhibition Hall of Achievements of China’s Language Resources Protection Project Officially Opens 
HotelKey Announces Strategic Leadership Updates to Expand Global Footprint and Drive Operational Excellence AltruBio Announces First Patient Dosed in Phase 1 Trial of Next-Generation Immune Checkpoint Enhancer ALTB-268 for the Treatment of Ulcerative Colitis
SAN FRANCISCO, Jan. 23, 2023 (GLOBE NEWSWIRE) — AltruBio Inc. (“AltruBio” or “the Company”), a…
Sofwave Gains Market Approval For SUPERB™ Non-Invasive Wrinkle Reduction and Lifting Technology in Mexico — the Second Largest Aesthetic Medical Market in Latin America
Approval granted by Mexico’s Food and Drug Administration, the Federal Commission for the Protection from…
RespireRx Pharmaceuticals Inc. Announces the 2nd Amendment to its License Agreement with the University of Illinois
Glen Rock, N.J., Jan. 23, 2023 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI)…
Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million
23 January 2023 Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million The deal includes…
Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®
CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (NASDAQ: CPRX),…
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
Acquisition of Worldwide Rights to Proleukin® Provides Immediate and Ongoing Revenue and Secures IL-2 Supply…
Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage…
CytoReason to License Its IBD Disease Model to Sanofi in Expanded Multiyear, Multimillion Dollar Deal
Collaboration will support Sanofi’s use of CytoReason’s computational disease models to develop new targets for…
Cue Biopharma Announces Chief Medical Officer Transition
Matteo Levisetti, M.D., promoted to Chief Medical Officer, effective January 17, 2023 Acting CMO Kenneth…
IO Biotech Announces Appointment of Devin Smith as General Counsel
Mr. Smith joins IO Biotech bringing over two decades of legal and compliance experience in…
Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome
– Patients reported clinically meaningful improvements across multiple health-related quality of life measures following 52…
Dr. Matt Cahill Appointed Chief Operating Officer of Qu Biologics
BURNABY, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) — Qu Biologics Inc., a clinical stage…
12-month clinical results of a novel micro-interventional bio-stenting procedure published in the British Journal of Ophthalmology
WHITE PLAINS, N.Y., Jan. 23, 2023 (GLOBE NEWSWIRE) — Iantrek today announced the publication of…
iSpecimen to Participate in the Sequire Biotechnology Conference on February 2, 2023
LEXINGTON, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the…
Intelligent Bio Solutions Reaches Key Milestone in Biosensor Platform Development
Achieves Record 4x Improvement in Time-To-Result to Provide Test Results in Under 1 Minute NEW YORK,…
Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
Overall response rate (ORR) of 23% and disease control rate (DCR) of 76% in expanded…
LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (Nasdaq:…
OncXerna Therapeutics Announces Final Results and New Xerna™ TME Panel Biomarker Data from a Phase 2 Trial of Bavituximab Plus Pembrolizumab in Patients with Previously Untreated Advanced Hepatocellular Carcinoma
Bavituximab plus pembrolizumab combination achieved a 62.5% response rate in biomarker positive subgroup of hepatocellular…
BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today…
Matinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023
Conference call and live audio webcast scheduled for Monday, January 30th at 4:30 p.m. ET…